Market Cap
$64.0M
INKT
MiNK Therapeutics, Inc.
$12.52 ▼ -1.61%
Prev close $12.73Market cap$64.0M
12-mo target$39.00 (+211.4%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on INKT right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
21 funds
Inst. Value
$2.2M
Inst. Activity
2 buys / 1 sells
Insider Activity
$0.00 buy / $46.6K sell
Insider Net $
-$46.6K
SEC Reports
6
Press Releases
10
Price chart 30d +10.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 fda
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT ), a clinical-sta
Sep 1, 2026 Insider
Behner Peter was granted 1,485 shares
Director @ $10.95 ($16.3K)
Sep 1, 2026 Insider
Ryan Barbara was granted 1,622 shares
Director @ $10.95 ($17.8K)
Sep 1, 2026 Insider
Aug 13, 2026 SEC Holcomb John Bradley was granted 1,233 shares
Director @ $10.95 ($13.5K)
MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with
PRESS-RELEASE — Impact 6/10
MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with
8-K — Impact 6/10
MiNK Therapeutics presented initial Phase 2 data at MHSRS showing first patients treated with agenT-797 for severe hypox
Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
13,382 shares ($156.4K)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Aug 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jul 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Price targets
Where 2 covering analysts think INKT trades over the next 12 months.
$39.00 +211.4% upside Strong Buy
Current$12.53 Low$35.00 Median$39.00 High$43.00 2 analysts
$35.00$43.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 2 bullish, 0 bearish, 2 mixed, 2 neutral · avg impact 5.3/10.Plus 10 press releases.
MIXEDPRESS-RELEASE6/10
MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/shar
Aug 13, 2026
MIXED8-K6/10
MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/shar
Aug 13, 2026
NEUTRAL8-K5/10
MiNK Therapeutics reported Q1 2026 results with a net loss of $2.7M ($0.57 per share), beating conse
May 15, 2026
BULLISHPRESS-RELEASE6/10
MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus of -$0.77 by 26%, with net loss
May 15, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
fda
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic
Aug 13, 2026
earnings
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc . (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-she
Aug 13, 2026
earnings_calendar
INKT Q2 2026 Earnings Before Market Open — 2026-08-13
Aug 12, 2026
earnings_calendar
INKT Q2 2026 Earnings Before Market Open — 2026-08-12
Aug 6, 2026
fda
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NSDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shel
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.35 | $-0.35–$-0.35 | 46.2% | +44.4% | 1↑ 0↓ | $0.0B | 1 |
| Next Q | $-0.39 | $-0.39–$-0.39 | 30.4% | +40.9% | 1↑ 0↓ | $0.0B | 1 |
| Current FY | $-1.93 | $-1.93–$-1.93 | 34.1% | +21.5% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $-2.65 | $-3.32–$-1.97 | -37.0% | +7.4% | 1↑ 0↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.350 | — |
| 7d ago | $-0.630 | +0.280 |
| 30d ago | $-0.630 | +0.280 |
| 60d ago | $-0.630 | +0.280 |
| 90d ago | $-0.910 | +0.560 |
Institutional ownership
Which big funds own INKT (from quarterly 13F filings) and who is adding or trimming.
21 institutional holders with $2.2M total value (186,199 shares) as of 2026-Q2. Top holders: VANGUARD, DnB, GEODE. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 68,660 | $802.6K | 36.9% | — |
| DnB Asset Management AS | 55,142 | $644.6K | 29.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 15,573 | $182.1K | 8.4% | — |
| CITADEL ADVISORS LLC | 15,440 | $180.5K | 8.3% | — |
| BlackRock, Inc. | 13,382 | $156.4K | 7.2% | DOUBLED +115.7% |
| VANGUARD FIDUCIARY TRUST CO | 8,287 | $96.9K | 4.5% | — |
| UBS Group AG | 4,885 | $57.1K | 2.6% | TRIM -67.9% |
| Steward Partners Investment Advisory, LLC | 2,000 | $23.4K | 1.1% | — |
| US BANCORP \DE\ | 1,995 | $23.3K | 1.1% | — |
| Federation des caisses Desjardins du Quebec | 500 | $5.8K | 0.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 6,203 | 13,382 | +115.7% | $156.4K |
| UBS Group AG | TRIM | 15,202 | 4,885 | -67.9% | $57.1K |
| OSAIC HOLDINGS, INC. | DOUBLED | 1 | 117 | +11600.0% | $1.4K |
| UBS Group AG | ADD | 9,548 | 15,202 | +59.2% | $160.1K |
| OSAIC HOLDINGS, INC. | NEAR_EXIT | 117 | 1 | -99.1% | $10.00 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | DOUBLED | 19 | 7,774 | +40815.8% | $2.7M |
| VANGUARD GROUP INC | DOUBLED | 33,351 | 67,651 | +102.8% | $754.3K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 14,600 | 10,400 | -28.8% | $116.0K |
| UBS Group AG | ADD | 5,648 | 9,548 | +69.1% | $106.5K |
| VANGUARD GROUP INC | ADD | 23,744 | 33,351 | +40.5% | $466.9K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 24 transactions. Net -$46.6K — $0.00 bought, $46.6K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Behner Peter | Director | AWARD | 1,485 | $10.95 | $16.3K |
| Sep 1, 2026 | Ryan Barbara | Director | AWARD | 1,622 | $10.95 | $17.8K |
| Sep 1, 2026 | Holcomb John Bradley | Director | AWARD | 1,233 | $10.95 | $13.5K |
| Sep 1, 2026 | Corvese Brian | Director | AWARD | 1,633 | $10.95 | $17.9K |
| Sep 1, 2026 | WIINBERG ULF | Director | AWARD | 1,279 | $10.95 | $14.0K |
| Jun 4, 2026 | Ryan Barbara | Director | SELL | 500 | $12.68 | $6.3K |
| Jun 4, 2026 | Ryan Barbara | Director | SELL | 1,000 | $12.80 | $12.8K |
| Jun 1, 2026 | Behner Peter | Director | AWARD | 1,313 | $12.38 | $16.3K |
| Jun 1, 2026 | Corvese Brian | Director | AWARD | 1,444 | $12.38 | $17.9K |
| Jun 1, 2026 | Holcomb John Bradley | Director | AWARD | 1,091 | $12.38 | $13.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for INKT.
Shares short
57,136
Settlement Sep 15, 2026
Change vs prior
-12.1%
Semi-monthly cycle
Days to cover
3.1
At avg daily volume
Of shares outstanding
≈1.1%
Estimate — not % of float
All INKT filing & press-release reports (16)
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportMay 28, 2026
- PRESS-RELEASE reportMay 20, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 15, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportMay 8, 2026
- 8-K reportApr 21, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 1, 2026
- PRESS-RELEASE reportMar 31, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 10, 2026